Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Waterloo University’s Drug for AMD and DME
Researchers have successfully developed a groundbreaking synthetic protein to treat macular degeneration and other currently incurable eye diseases leading to blindness in millions of individuals. This pioneering drug, currently undergoing human trials, is the first of its kind. With over…
€1.8M Research Tax Credit to Pixium Provided to Pixium
Pixium Vision SA has announced the reception of a €1.8 million Research Tax Credit from the French government. The funds received will enable the company to extend its cash runway until the end of September 2023, offering greater flexibility to…
Novartis to Halt Development of GA Gene Therapy
After observing discouraging phase 2 clinical data, Novartis has opted to terminate the clinical advancement of its geographic atrophy gene therapy candidate GT005, a product it acquired through the acquisition of Gyroscope Therapeutics. The announcement was officially disseminated by investment…
What Is Bull’s Eye Maculopathy and How to Manage It
What Is Bull’s Eye Maculopathy? Bull’s Eye Maculopathy is a specific form of retinal disease characterized by changes in the pigmentation of the macular region of the retina, often presenting as a ‘bull’s eye’ pattern. The macula is the central…
Iveric Bio’s Izervay for Geographic Atrophy Approved by FDA
Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…
Best Treatment for Uveitic Macular Edema Identified
Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…
Aegis and Northwell Launch AI Company Optain
Ascertain, a joint venture between Aegis Ventures and Northwell Holdings, has raised $12 million in seed funding to launch Optain, an AI company that utilizes retinal imaging for early disease detection and prevention. Optain’s AI technology analyzes data from a…
Tenpoint Therapeutics Launches with $70M Financing
Tenpoint Therapeutics, a biotechnology company focused on vision-restoring engineered cell-based therapeutics and in vivo reprogramming for degenerative ocular diseases, has announced its launch with a $70 million Series A financing. The funding will be used to develop the company’s regenerative…
Naegis Pharma Funds Novel Eye Drug
Naegis Pharmaceuticals Inc., a life sciences company specializing in inflammation and ophthalmology, announced the successful closure of a financing round to advance its lead compound, N0651, towards a Phase 2 clinical trial. This funding will support the compound’s progression through…
2023 Recap: Top 10 Contact Lenses and Technologies
In the ever-evolving landscape of ophthalmology, 2023 has proven to be a year of groundbreaking advancements in contact lens technology. From lenses that adapt to UV and temperature changes to intelligent lenses capable of diagnosing and treating glaucoma, the top…